nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—DRD2—nicotine dependence	0.769	1	CbGaD
Amphetamine—Dysphoria—Varenicline—nicotine dependence	0.00905	0.0846	CcSEcCtD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA6—nicotine dependence	0.0078	0.07	CbGpPWpGaD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA5—nicotine dependence	0.00502	0.0451	CbGpPWpGaD
Amphetamine—CYP2A6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00471	0.0422	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00461	0.0413	CbGpPWpGaD
Amphetamine—Accidental injury—Varenicline—nicotine dependence	0.00442	0.0413	CcSEcCtD
Amphetamine—Viral infection—Varenicline—nicotine dependence	0.00433	0.0405	CcSEcCtD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA3—nicotine dependence	0.0041	0.0367	CbGpPWpGaD
Amphetamine—Blood pressure increased—Varenicline—nicotine dependence	0.00391	0.0366	CcSEcCtD
Amphetamine—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA6—nicotine dependence	0.00373	0.0335	CbGpPWpGaD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNB2—nicotine dependence	0.00361	0.0324	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—DRD2—nicotine dependence	0.00341	0.0306	CbGpPWpGaD
Amphetamine—Euphoric mood—Varenicline—nicotine dependence	0.00336	0.0314	CcSEcCtD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA4—nicotine dependence	0.00327	0.0294	CbGpPWpGaD
Amphetamine—TAAR1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0032	0.0287	CbGpPWpGaD
Amphetamine—Injury—Varenicline—nicotine dependence	0.00309	0.0289	CcSEcCtD
Amphetamine—Libido decreased—Varenicline—nicotine dependence	0.00306	0.0286	CcSEcCtD
Amphetamine—CYP2A6—Xenobiotics—CYP2A7—nicotine dependence	0.00292	0.0262	CbGpPWpGaD
Amphetamine—Cerebrovascular accident—Varenicline—nicotine dependence	0.0029	0.0271	CcSEcCtD
Amphetamine—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00282	0.0263	CcSEcCtD
Amphetamine—Affect lability—Varenicline—nicotine dependence	0.0028	0.0261	CcSEcCtD
Amphetamine—Psychotic disorder—Varenicline—nicotine dependence	0.00277	0.0259	CcSEcCtD
Amphetamine—Irritability—Varenicline—nicotine dependence	0.00271	0.0253	CcSEcCtD
Amphetamine—Mood swings—Varenicline—nicotine dependence	0.00269	0.0251	CcSEcCtD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD2—nicotine dependence	0.00267	0.0239	CbGpPWpGaD
Amphetamine—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00264	0.0237	CbGpPWpGaD
Amphetamine—Abdominal pain upper—Varenicline—nicotine dependence	0.00259	0.0242	CcSEcCtD
Amphetamine—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA5—nicotine dependence	0.00241	0.0216	CbGpPWpGaD
Amphetamine—Erectile dysfunction—Varenicline—nicotine dependence	0.00226	0.0211	CcSEcCtD
Amphetamine—Photosensitivity reaction—Varenicline—nicotine dependence	0.00224	0.0209	CcSEcCtD
Amphetamine—Depression—Varenicline—nicotine dependence	0.00218	0.0204	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00217	0.0203	CcSEcCtD
Amphetamine—CARTPT—brain—nicotine dependence	0.00216	0.166	CbGeAlD
Amphetamine—Acute coronary syndrome—Varenicline—nicotine dependence	0.00216	0.0202	CcSEcCtD
Amphetamine—Myocardial infarction—Varenicline—nicotine dependence	0.00215	0.0201	CcSEcCtD
Amphetamine—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00206	0.0185	CbGpPWpGaD
Amphetamine—MAOB—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00202	0.0181	CbGpPWpGaD
Amphetamine—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA3—nicotine dependence	0.00196	0.0176	CbGpPWpGaD
Amphetamine—Erythema multiforme—Varenicline—nicotine dependence	0.00186	0.0174	CcSEcCtD
Amphetamine—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNB2—nicotine dependence	0.00173	0.0155	CbGpPWpGaD
Amphetamine—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00164	0.0147	CbGpPWpGaD
Amphetamine—Tremor—Varenicline—nicotine dependence	0.0016	0.015	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00157	0.0141	CbGpPWpGaD
Amphetamine—Agitation—Varenicline—nicotine dependence	0.00157	0.0147	CcSEcCtD
Amphetamine—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA4—nicotine dependence	0.00157	0.0141	CbGpPWpGaD
Amphetamine—Angioedema—Varenicline—nicotine dependence	0.00156	0.0146	CcSEcCtD
Amphetamine—Palpitations—Varenicline—nicotine dependence	0.00151	0.0141	CcSEcCtD
Amphetamine—Convulsion—Varenicline—nicotine dependence	0.00148	0.0139	CcSEcCtD
Amphetamine—Hypertension—Varenicline—nicotine dependence	0.00148	0.0138	CcSEcCtD
Amphetamine—Chest pain—Varenicline—nicotine dependence	0.00146	0.0136	CcSEcCtD
Amphetamine—Anxiety—Varenicline—nicotine dependence	0.00145	0.0136	CcSEcCtD
Amphetamine—Dry mouth—Varenicline—nicotine dependence	0.00142	0.0133	CcSEcCtD
Amphetamine—Infection—Varenicline—nicotine dependence	0.00139	0.013	CcSEcCtD
Amphetamine—Tachycardia—Varenicline—nicotine dependence	0.00136	0.0127	CcSEcCtD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00136	0.0122	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Varenicline—nicotine dependence	0.00135	0.0126	CcSEcCtD
Amphetamine—Anorexia—Varenicline—nicotine dependence	0.00133	0.0124	CcSEcCtD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.00129	0.0115	CbGpPWpGaD
Amphetamine—Insomnia—Varenicline—nicotine dependence	0.00126	0.0118	CcSEcCtD
Amphetamine—Dyspnoea—Varenicline—nicotine dependence	0.00124	0.0116	CcSEcCtD
Amphetamine—Somnolence—Varenicline—nicotine dependence	0.00124	0.0116	CcSEcCtD
Amphetamine—Dyspepsia—Varenicline—nicotine dependence	0.00123	0.0115	CcSEcCtD
Amphetamine—Decreased appetite—Varenicline—nicotine dependence	0.00121	0.0113	CcSEcCtD
Amphetamine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00121	0.0109	CbGpPWpGaD
Amphetamine—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00121	0.0113	CcSEcCtD
Amphetamine—Fatigue—Varenicline—nicotine dependence	0.0012	0.0112	CcSEcCtD
Amphetamine—CYP2A6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0012	0.0107	CbGpPWpGaD
Amphetamine—Constipation—Varenicline—nicotine dependence	0.00119	0.0112	CcSEcCtD
Amphetamine—SLC18A2—midbrain—nicotine dependence	0.00117	0.09	CbGeAlD
Amphetamine—Gastrointestinal pain—Varenicline—nicotine dependence	0.00114	0.0107	CcSEcCtD
Amphetamine—Urticaria—Varenicline—nicotine dependence	0.00111	0.0104	CcSEcCtD
Amphetamine—Body temperature increased—Varenicline—nicotine dependence	0.0011	0.0103	CcSEcCtD
Amphetamine—Abdominal pain—Varenicline—nicotine dependence	0.0011	0.0103	CcSEcCtD
Amphetamine—MAOB—Biological oxidations—CYP2A7—nicotine dependence	0.00107	0.00961	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—CHRNB3—nicotine dependence	0.00104	0.00932	CbGpPWpGaD
Amphetamine—Hypersensitivity—Varenicline—nicotine dependence	0.00103	0.00961	CcSEcCtD
Amphetamine—Asthenia—Varenicline—nicotine dependence	0.001	0.00936	CcSEcCtD
Amphetamine—MAOB—cardiovascular system—nicotine dependence	0.000985	0.076	CbGeAlD
Amphetamine—SLC18A2—Neuronal System—CHRNA6—nicotine dependence	0.000985	0.00883	CbGpPWpGaD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000983	0.00881	CbGpPWpGaD
Amphetamine—Diarrhoea—Varenicline—nicotine dependence	0.000955	0.00893	CcSEcCtD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.000929	0.00833	CbGpPWpGaD
Amphetamine—Dizziness—Varenicline—nicotine dependence	0.000923	0.00863	CcSEcCtD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.000891	0.00799	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00089	0.00798	CbGpPWpGaD
Amphetamine—Vomiting—Varenicline—nicotine dependence	0.000888	0.0083	CcSEcCtD
Amphetamine—SLC6A3—midbrain—nicotine dependence	0.000883	0.0681	CbGeAlD
Amphetamine—Rash—Varenicline—nicotine dependence	0.00088	0.00823	CcSEcCtD
Amphetamine—Dermatitis—Varenicline—nicotine dependence	0.000879	0.00822	CcSEcCtD
Amphetamine—Headache—Varenicline—nicotine dependence	0.000875	0.00817	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000872	0.00782	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00085	0.00763	CbGpPWpGaD
Amphetamine—Nausea—Varenicline—nicotine dependence	0.000829	0.00775	CcSEcCtD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.000828	0.00743	CbGpPWpGaD
Amphetamine—SLC6A4—midbrain—nicotine dependence	0.000809	0.0624	CbGeAlD
Amphetamine—TAAR1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000808	0.00725	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.000808	0.00725	CbGpPWpGaD
Amphetamine—MAOB—midbrain—nicotine dependence	0.000769	0.0593	CbGeAlD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.000766	0.00687	CbGpPWpGaD
Amphetamine—SLC18A2—brain—nicotine dependence	0.000734	0.0566	CbGeAlD
Amphetamine—SLC18A2—Neuronal System—GABRA4—nicotine dependence	0.000712	0.00639	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—FGD1—nicotine dependence	0.000698	0.00627	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—CHRNB4—nicotine dependence	0.000682	0.00612	CbGpPWpGaD
Amphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00068	0.0061	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.000675	0.00606	CbGpPWpGaD
Amphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000671	0.00602	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—OPRM1—nicotine dependence	0.000664	0.00596	CbGpPWpGaD
Amphetamine—CYP2A6—brain—nicotine dependence	0.000655	0.0505	CbGeAlD
Amphetamine—DRD2—midbrain—nicotine dependence	0.000649	0.0501	CbGeAlD
Amphetamine—SLC18A2—Neuronal System—CHRNA5—nicotine dependence	0.000634	0.00569	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—FGD1—nicotine dependence	0.000634	0.00569	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00063	0.00565	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—CHRNB3—nicotine dependence	0.000619	0.00555	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000607	0.00544	CbGpPWpGaD
Amphetamine—SLC22A5—midbrain—nicotine dependence	0.000605	0.0466	CbGeAlD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.000594	0.00533	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—CHRNA6—nicotine dependence	0.000587	0.00527	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.000567	0.00509	CbGpPWpGaD
Amphetamine—SLC6A3—brain—nicotine dependence	0.000555	0.0428	CbGeAlD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.000554	0.00497	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000551	0.00494	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.00054	0.00484	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.000531	0.00476	CbGpPWpGaD
Amphetamine—SLC22A3—brain—nicotine dependence	0.000522	0.0403	CbGeAlD
Amphetamine—CYP2A6—Biological oxidations—CYP2A7—nicotine dependence	0.000522	0.00468	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—CHRNA3—nicotine dependence	0.000517	0.00464	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000515	0.00462	CbGpPWpGaD
Amphetamine—SLC6A4—brain—nicotine dependence	0.000509	0.0392	CbGeAlD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.000494	0.00443	CbGpPWpGaD
Amphetamine—MAOB—brain—nicotine dependence	0.000483	0.0373	CbGeAlD
Amphetamine—TAAR1—GPCR ligand binding—DRD2—nicotine dependence	0.00048	0.00431	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TAS2R16—nicotine dependence	0.000477	0.00428	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000463	0.00416	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—CHRNB2—nicotine dependence	0.000455	0.00409	CbGpPWpGaD
Amphetamine—SLC6A2—brain—nicotine dependence	0.000448	0.0345	CbGeAlD
Amphetamine—SLC6A3—Neuronal System—GABRA4—nicotine dependence	0.000424	0.00381	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—CHRNA4—nicotine dependence	0.000413	0.00371	CbGpPWpGaD
Amphetamine—DRD2—brain—nicotine dependence	0.000408	0.0315	CbGeAlD
Amphetamine—SLC6A3—Neuronal System—CHRNB4—nicotine dependence	0.000407	0.00365	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.000402	0.00361	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000383	0.00343	CbGpPWpGaD
Amphetamine—SLC22A5—brain—nicotine dependence	0.00038	0.0293	CbGeAlD
Amphetamine—SLC6A3—Neuronal System—CHRNA5—nicotine dependence	0.000378	0.00339	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000375	0.00337	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—FGD1—nicotine dependence	0.000375	0.00336	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—TAS2R16—nicotine dependence	0.000367	0.0033	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.000354	0.00318	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—DRD2—nicotine dependence	0.000342	0.00307	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—OPRM1—nicotine dependence	0.000341	0.00306	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000331	0.00297	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKR1B10—nicotine dependence	0.000331	0.00297	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00033	0.00296	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000322	0.00289	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000311	0.00279	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—CHRNA3—nicotine dependence	0.000308	0.00277	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000293	0.00263	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000289	0.00259	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000283	0.00254	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—CHRNB2—nicotine dependence	0.000271	0.00244	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—DRD2—nicotine dependence	0.000271	0.00243	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000258	0.00231	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000256	0.00229	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—CHRNA4—nicotine dependence	0.000246	0.00221	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—DRD2—nicotine dependence	0.000246	0.00221	CbGpPWpGaD
Amphetamine—CYP2D6—brain—nicotine dependence	0.000245	0.0189	CbGeAlD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000237	0.00213	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—WASF2—nicotine dependence	0.000233	0.00209	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000228	0.00205	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—WASF1—nicotine dependence	0.000224	0.00201	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000208	0.00186	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000203	0.00182	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—OPRM1—nicotine dependence	0.000201	0.00181	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—TAS2R16—nicotine dependence	0.000188	0.00169	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP2A7—nicotine dependence	0.000183	0.00164	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—FGD1—nicotine dependence	0.000163	0.00146	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP2A7—nicotine dependence	0.000155	0.00139	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—OPRM1—nicotine dependence	0.000155	0.00139	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—FGD1—nicotine dependence	0.000148	0.00133	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD2—nicotine dependence	0.000146	0.00131	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TAS2R16—nicotine dependence	0.000111	0.000999	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP2A7—nicotine dependence	8.93e-05	0.000801	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—OPRM1—nicotine dependence	8.75e-05	0.000785	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGD1—nicotine dependence	8.74e-05	0.000784	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—OPRM1—nicotine dependence	7.95e-05	0.000713	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKR1B10—nicotine dependence	7.72e-05	0.000692	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—WASF2—nicotine dependence	5.44e-05	0.000488	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—WASF1—nicotine dependence	5.21e-05	0.000468	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP2A7—nicotine dependence	5.01e-05	0.000449	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—OPRM1—nicotine dependence	4.69e-05	0.000421	CbGpPWpGaD
